Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries
- DOI
- 10.1007/s40259-025-00709-1
- Published
- 2025-02-25
- Container
- BioDrugs
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40259-025-00709-1,
title = {Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries},
author = {Alexander C. T. Tam and Jasleen Badesha and Daphne P. Guh and Nick Bansback and Kevin K. Peter and Aidan Hollis and Paul Grootendorst and Sang-Cheol Bae and Aslam H. Anis and Wei Zhang},
year = {2025},
journal = {BioDrugs},
doi = {10.1007/s40259-025-00709-1},
url = {https://doi.org/10.1007/s40259-025-00709-1}
}RIS
TY - JOUR TI - Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries AU - Alexander C. T. Tam AU - Jasleen Badesha AU - Daphne P. Guh AU - Nick Bansback AU - Kevin K. Peter AU - Aidan Hollis AU - Paul Grootendorst AU - Sang-Cheol Bae AU - Aslam H. Anis AU - Wei Zhang PY - 2025 JO - BioDrugs DO - 10.1007/s40259-025-00709-1 UR - https://doi.org/10.1007/s40259-025-00709-1 ER -
APA
Tam, A. C. T., Badesha, J., Guh, D. P., Bansback, N., Peter, K. K., Hollis, A., Grootendorst, P., Bae, S., Anis, A. H., & Zhang, W. (2025). Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries. BioDrugs. https://doi.org/10.1007/s40259-025-00709-1
Source records
- crossref · retrieved 2026-09-25T03:34:48.809Z